Exploiting Controlled Environments for the Development of Optimised Cannabis Sativa Phenotypes for Pharmaceutical Applications - CE-CannPharm

制药行业相对成熟，并以大量日益复杂的科学，技术以及最近的人工智能方法为基础。尽管有90%的临床药物开发失败，但全球人口统计学的演变正在推动退行性和神经退行性/功能障碍性疾病的数量增加，这使得制药公司将重点扩大到基于自然的疗法，并在这里接受长期已知的，越来越多的临床支持，下议院图书馆最近的一份研究简报报告指出，英国是世界上最大的法律的大麻生产国和出口国。用于医疗和科学目的的大麻，Prohibition Partners预计到2026年英国的价值为10亿英镑，Statista估计全球市场的收入已经超过130亿英镑。然而，用于制药行业的大麻存在一个问题，因为大麻素谱随着植物中的位置而变化，其中花的化学谱在顶部，中间和底部显示出+/-20%（或更大）数量级的变化，这显著超过了=+/-10%的典型药物产品公差。这就给C.Sativa带来了一个主要的一致性和分级问题，当它被认为是一种药物时。在这里，我们与我们的行业合作伙伴Glass Pharms Ltd合作，旨在通过几种途径解决这个问题。通过筛选不同的C.Sativa种质，我们将建立植物结构变异，目的是探索最终创造具有改变结构的C.Sativa植物的潜力：更少的“圣诞树”和更多的“烛台”形状，花序（花）更均匀地呈现在入射光下。这将对花的生物活性成分和重要的方差redcution.We产生积极的影响也将期待通过矮化C.Sativa通过既定的方法和探索的潜力，总控制的环境农业垂直农业在这里，以提高生产力和减少方差。这种对环境的绝对控制将使我们能够在作物发育过程中充分利用VF嵌入式灯的可调光强度和波长，从而有机会“调整”大麻大麻素和萜类化合物的含量、组成和变化。与此相关联，我们将阐明基因和代谢物水平上的光/植物相互作用，以确定重要的基因级联，以期通过传统或现代方法确定未来开发的基因靶标/标记。（基因改造/基因编辑）育种方法。在这里，作为JHI和Glass Pharms Ltd合作的一部分，这两家公司都是高TCH大麻生产许可证持有者，我们将提供以下内容：大大提高了大麻中所含活性药物成分在同一植物不同花序（花）中分布的一致性。CAE/VF系统更好地标准化了品种表型，目标是矮化和统一的表型。定义了操作/定义大麻素含量和组成的条件和过程。在更广泛的背景下，计划中的研究支持了英国许多政策目标，包括高价值部门的经济增长与相关的永久性高技能工作，改善不断变化的人口的医疗保健以及英国农业基础的多样化。这里提出的科学将支持并帮助保持英国作为药用大麻生产商和出口商的领先地位。

The pharmaceutical industry is relatively mature and underpinned with a plethora of increasing sophisticated science, technology, and more recently, AI approaches. Despite this 90% of clinical drug development fails but global demographic evolution is driving increased numbers of degenerative and neurodegenerative/dysfunctional disease, and this has seen pharma broaden their focus to nature-based therapies and, here, embrace the long-known, and increasingly clinically underpinned, benefits of medicinal cannabis.A recent research briefing from the House of Commons Library report identified that the UK is the world's biggest producer and exporter of legal cannabis for medical and scientific purposes with Prohibition Partners projecting a UK value of £1Bn by 2026 and Statista estimating a global market already in excess of £13Bn in revenue.However, there is a problem with cannabis for the pharmaceutical industry in that the cannabinoid profile changes with location in the plant with the chemo-profiles of the flowers at the top, middle and bottom showing a variance of an order of +/-20% (or more), which is significantly beyond a typical pharmaceutical product tolerance of =+/-10%. This creates a major consistency and grading problem for C.Sativa when it is considered as a pharmaceutical medicine.Here, with our industry partners Glass Pharms Ltd, we aim to address this via several avenues. Via a screen of diverse C.Sativa germplasm we will establish plant architecture variation with the aim of exploring the potential of ultimately creating C.Sativa plants with an altered architecture: less "Christmas tree"- and more "menorah"-shaped, with inflorescence (flowers) more even presented to the incident light. This should impact positively on flower bioactive content composition and importantly variance redcution.We will also look to increase productivity and reduced variance by dwarfing C.Sativa through established methods and exploring the potential of total controlled environmental agriculture here by vertical farming. This absolute control on the environment will allow us to fully exploit the tuneable light intensity and wavelengths of the VF-embedded lights across crop development offering the opportunity to also "tune" the cannabis cannabinoid and terpenoid content, composition and variance. Allied to this we will elucidate the light/plant interactions at the gene and metabolite levels to identify the important gene cascades with a view to identifying gene targets/markers for future exploitation via traditional or modern (genetic modification/gene editing) breeding approaches.Here as part of a collaboration between JHI and Glass Pharms Ltd, both high TCH cannabis production licence holders, we will deliver the following: Greatly improved consistency in the distribution of the active pharmaceutical ingredients contained in Cannabis Sativa across different inflorescence (flowers) on the same plant.Better standardisation of cultivar phenotypes for CAE/VF systems with a target for dwarfed and uniform phenotypes.Defined conditions and process to manipulate/define cannabinoid content and composition. In a wider context the planned research underpins many of the UK policy targets in terms of high-value sector economic growth with associated permanent highly skilled jobs, improvement of healthcare for an evolving demographic and the diversification of the UK agricultural base. The proposed science here will underpin and help maintain the UK's lead as a medicinal cannabis producer and exported.